3,000 Shares in ADMA Biologics, Inc. (NASDAQ:ADMA) Acquired by Vision Financial Markets LLC

Vision Financial Markets LLC bought a new position in ADMA Biologics, Inc. (NASDAQ:ADMA) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 3,000 shares of the biotechnology company’s stock, valued at approximately $51,000.

Several other hedge funds have also modified their holdings of the stock. Hollencrest Capital Management acquired a new position in ADMA Biologics during the third quarter valued at approximately $30,000. Larson Financial Group LLC acquired a new position in ADMA Biologics during the third quarter valued at approximately $31,000. National Bank of Canada FI acquired a new position in ADMA Biologics during the third quarter valued at approximately $35,000. GAMMA Investing LLC lifted its position in ADMA Biologics by 106.6% during the fourth quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company’s stock valued at $32,000 after buying an additional 967 shares in the last quarter. Finally, Harvest Fund Management Co. Ltd acquired a new position in ADMA Biologics during the third quarter valued at approximately $62,000. 75.68% of the stock is owned by institutional investors and hedge funds.

ADMA Biologics Trading Up 3.9 %

NASDAQ ADMA opened at $17.68 on Thursday. The company’s fifty day simple moving average is $16.69 and its 200-day simple moving average is $17.97. ADMA Biologics, Inc. has a 52 week low of $5.71 and a 52 week high of $23.64. The company has a current ratio of 7.09, a quick ratio of 3.26 and a debt-to-equity ratio of 0.48. The stock has a market cap of $4.18 billion, a P/E ratio of 63.14 and a beta of 0.75.

Analysts Set New Price Targets

ADMA has been the topic of a number of recent research reports. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $25.00 price target on shares of ADMA Biologics in a research report on Tuesday. HC Wainwright lifted their price target on shares of ADMA Biologics from $18.00 to $26.00 and gave the company a “buy” rating in a research report on Friday, November 8th. Finally, Raymond James lifted their price target on shares of ADMA Biologics from $18.00 to $25.00 and gave the company a “strong-buy” rating in a research report on Friday, November 8th.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.